Resultats de la cerca - Adam Kashishian

  • Mostrar 1 - 10 resultats de 10
Refinar resultats
  1. 1
    Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo.

    Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo. per Adam Kashishian, Andrius Kazlauskas, Jonathan A. Cooper

    Publicat 1992
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    GTPase-activating protein and phosphatidylinositol 3-kinase bind to distinct regions of the platelet-derived growth factor receptor beta subunit.

    GTPase-activating protein and phosphatidylinositol 3-kinase bind to distinct regions of the platelet-derived growth factor receptor beta subunit. per Andrius Kazlauskas, Adam Kashishian, Jonathan A. Cooper, Mindaugas Valius

    Publicat 1992
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor.

    Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor. per Riko Nishimura, W Li, Adam Kashishian, Anna Mondino, Min Zhou, Jonathan A. Cooper, Joseph Schlessinger

    Publicat 1993
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    AKAP79 Inhibits Calcineurin through a Site Distinct from the Immunophilin-binding Region

    AKAP79 Inhibits Calcineurin through a Site Distinct from the Immunophilin-binding Region per Adam Kashishian, Monique Howard, Christine Loh, W. Michael Gallatin, Merl F. Hoekstra, Yvonne Y. Lai

    Publicat 1998
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

    PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma per Sarah Meadows, Francisco Vega, Adam Kashishian, Dave Johnson, Volker Diehl, Langdon L. Miller, Anas Younes, Brian J. Lannutti

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor.

    Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor. per Robert J. Lechleider, Satoru Sugimoto, Anton M. Bennett, Adam Kashishian, Jonathan A. Cooper, Steven E. Shoelson, Christopher T. Walsh, Benjamin G. Neel

    Publicat 1993
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    p110δ, a Novel Phosphatidylinositol 3-Kinase Catalytic Subunit That Associates with p85 and Is Expressed Predominantly in Leukocytes

    p110δ, a Novel Phosphatidylinositol 3-Kinase Catalytic Subunit That Associates with p85 and Is Expressed Predominantly in Leukocytes per David Chantry, Anne B. Vojtek, Adam Kashishian, Douglas A. Holtzman, Christi L. Wood, Patrick W. Gray, Jonathan A. Cooper, Merl F. Hoekstra

    Publicat 1997
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    DNA-Dependent Protein Kinase Is a Molecular Target for the Development of Noncytotoxic Radiation–Sensitizing Drugs

    DNA-Dependent Protein Kinase Is a Molecular Target for the Development of Noncytotoxic Radiation–Sensitizing Drugs per Eric T. Shinohara, Ling Geng, Jiahui Tan, Heidi Chen, Yu Shir, E. Edwards, James Halbrook, Edward A. Kesicki, Adam Kashishian, Dennis E. Hallahan

    Publicat 2005
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Targeting Nonclassical Oncogenes for Therapy in T-ALL

    Targeting Nonclassical Oncogenes for Therapy in T-ALL per Prem S. Subramaniam, Dosh Whye, Evgeni Efimenko, Jianchung Chen, Valeria Tosello, Kim De Keersmaecker, Adam Kashishian, Mary Ann Thompson, Mireia Castillo‐Martin, Carlos Cordón-Cardo, Utpal P. Davé, Adolfo A. Ferrando, Brian J. Lannutti, Thomas G. Diacovo

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

    CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability per Brian J. Lannutti, Sarah Meadows, Sarah E.M. Herman, Adam Kashishian, Bart Steiner, Amy J. Johnson, John C. Byrd, Jeffrey W. Tyner, Marc Loriaux, Mike Deininger, Brian J. Druker, Kamal D. Puri, Roger G. Ulrich, Neill A. Giese

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: